Corteva is expected to see significant upside potential as it sharpens its focus on agricultural chemical operations, according to JPMorgan Chase & Co. The investment bank upgraded the company’s stock from neutral to overweight, citing a $19 price target that implies approximately 53% upside from recent trading levels. The optimism stems from Corteva’s strategic shift following its recent spinoff of the seed business into a separate entity known as Vylor, allowing the company to prioritize its core agricultural chemical segment. “Corteva is the cast off: and we think it is undervalued at the current price,” said JPMorgan analyst Jeffrey Zekauskas in a client note dated Tuesday. He emphasized that the company’s new strategic direction involves in-licensing innovative crop chemical molecules from industry partners, which typically offer strong growth trajectories and above-average profit margins. Zekauskas also pointed to the company’s ability to navigate ongoing legal challenges, including litigation related to the use of certain chemical compounds in its products. Additionally, improving trends in agricultural commodity markets may provide further tailwinds for Corteva’s performance. “The crop chemical industry has faced declining price pressures over the last three years as corn prices declined from more than $6.00 per bushel to roughly $4.00 per bushel,” Zekauskas explained. “With corn prices now hovering around $5.00 per bushel, there is potential for stable to positive pricing dynamics heading into 2027, which our current model does not yet reflect.” This positive outlook aligns with broader market sentiment. According to Refinitiv data, 15 out of 23 analysts covering Corteva maintain a buy or strong buy recommendation on the stock. Despite a 6% decline over the past month—partly attributed to the spinoff process and unresolved legal matters—the stock remains up 23% year-to-date.
Source link
